Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
June 01, 2024 08:15 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Analysis of the Global Sepsis Pipeline, 2024 with Insights on 30+ Companies and 35+ Pipeline Drugs, Including Thymosin Alpha 1 (Sci Clone Pharmaceuticals) and Enibarcimab (AdrenoMed)
May 31, 2024 06:18 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Sepsis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about...
Fusion Fuel Announces First Quarter 2024 Webcast Date
May 31, 2024 06:00 ET
|
Fusion Fuel Green Public Limited Company
Fusion Fuel will hold its 1Q24 earnings call on June 5th at 10:00am ET
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
May 31, 2024 01:00 ET
|
BioSenic
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 31 mai 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée...
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
May 30, 2024 16:05 ET
|
Larimar Therapeutics
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseasesNomlabofusp was selected based on potential for...
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May 30, 2024 16:05 ET
|
NextCure
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3...
Ambarella, Inc. Announces First Quarter Fiscal Year 2025 Financial Results
May 30, 2024 16:05 ET
|
Ambarella
SANTA CLARA, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced financial results for its first quarter of fiscal year 2025...
OSE Immunotherapeutics fait le point sur ses avancées et sur la stratégie de croissance de la Société
May 30, 2024 12:15 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics fait le point sur ses avancées et sur la stratégie de croissance de la Société Trois accords pharmaceutiques signés au cours des trois derniers mois : Un nouveau partenariat...
OSE Immunotherapeutics Provides Business and Corporate Update
May 30, 2024 12:15 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months: New strategic partnership with AbbVie for OSE-230, a novel...
LIS Technologies Inc. Bolsters its Expertise with the Appointment of Prof David N. Ruzic as Chairman of the Executive Advisory Board for Plasma and Nuclear Technologies
May 30, 2024 12:00 ET
|
LIS Technologies Inc.
New York, N.Y., May 30, 2024 (GLOBE NEWSWIRE) -- LIS Technologies Inc. (“LIST” or “the Company”), a proprietary developer of advanced laser technology and the only USA-origin and patented laser...